These findings suggest that early inhibition of IL-1β–IL-1R signaling can suppress LCN2-driven tumor progression and that combining anakinra with STAT3 inhibition is a promising therapeutic strategy for lung cancer brain metastasis. Here, LCN2 is linked to lung cancer.